Cargando…
Neuroendocrinal, Neurodevelopmental, and Embryotoxic Effects of Recombinant Tissue Plasminogen Activator Treatment for Pregnant Women with Acute Ischemic Stroke
Thrombolysis with recombinant tissue plasminogen activator (rTPA) was the first evidence-based treatment approved for acute stroke. Ischemic stroke is relatively uncommon in fertile women but treatment is often delayed or not given. In randomized trials, pregnancy has been an exclusion criterion for...
Autores principales: | Steinberg, Anna, Moreira, Tiago P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766278/ https://www.ncbi.nlm.nih.gov/pubmed/26941596 http://dx.doi.org/10.3389/fnins.2016.00051 |
Ejemplares similares
-
Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2016) -
Quantitatively monitoring acute ischemic stroke patients post recombinant tissue plasminogen activator treatment
por: Liu, Yonge, et al.
Publicado: (2020) -
Severe Embryotoxicity of Artemisinin Derivatives in Experimental Animals, but Possibly Safe in Pregnant Women
por: Li, Qigui, et al.
Publicado: (2009) -
Cost-Effectiveness of Recombinant Tissue Plasminogen Activator in the Management of Acute Ischemic Stroke: A Systematic Review
por: Jung, Kee-Taig, et al.
Publicado: (2010) -
Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke
por: Tseng, Yi-Ju, et al.
Publicado: (2020)